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SI Materials and Methods
Materials.FP-biotin (1, 2) and FP-rhodamine (3) were synthesized
following previously described protocols. Demethylated-specific
PP2A (clone 4b7), methylated-specific PP2A (clone 2A10), total
PP2A, and PME-1 antibodies were purchased from Millipore.
Anti α-tubulin antibodies were purchased from NeoMarkers.
Recombinant PME-1 Protein Expression and Purification. Human
wild-type PME-1 was subcloned into the expression vector
pET-45b(+) (Novagen). BL21 (DE3) Escherichia coli containing
this vector was grown in LB media containing 75 mg∕L carbeni-
cillin with shaking at 37 °C to an OD600 of 0.5. The cells were then
induced with 1 mM IPTG and harvested 4 h later by centrifuga-
tion. Cells were lysed by stirring for 20 mins at 4 °C in 50 mMTris-
HCl (pH 8.0) with 150 mM NaCl and supplemented with
1 mg∕mL lysozyme and 1 mg∕mL DNase I. The lysate was then
sonicated and centrifuged at 10;000 × g for 10 min. Talon cobalt
affinity resin (Clontech; 400 μL of slurry/g of cell paste) was
added to the supernatant, and the mixture was rotated at room
temperature for 1 h. Beads were collected by centrifugation at
700 × g for 3 min, washed twice with Tris buffer, and applied
to a 1 cm column. The column was washed twice with Tris buffer
(10 mL∕400 μL of resin slurry) and Tris buffer with 500 mM
NaCl once. The bound protein was eluted by the addition of
100 mM imidazole (2 mL∕400 μL of resin). Imidazole was re-
moved by passage over a Sephadex G-25M column (GE Health-
care). Protein concentration was determined using the BioRad
DC Protein Assay kit. These conditions yielded pure (>95%
by SDS/PAGE) PME-1 at approximately 5 mg∕L of culture. A
S156A mutation was introduced into the pET-45b(+) construct
using the Quikchange Site-Directed Mutagenesis Kit (Strata-
gene), and the resulting mutant protein was expressed identically
and isolated with a similar yield.
PME-1 Fluopol-ABPPAssay.Prior to the start of the assay, 4.0 μL of
Assay Buffer [0.01% Pluronic F-127 (Invitrogen), 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM DTT (Invitrogen)] contain-
ing 1.25 μM of PME-1 protein was dispensed into 1536 micro-
titer plates. Next, 30 nL of test compound in DMSO or DMSO
alone (0.59% final concentration DMSO; 5.9 μM compound)
was added to the appropriate wells and incubated for 30 minutes
at 25 °C. The assay was started by dispensing 1.0 μL of 375 nM
FP-Rh probe in assay buffer to all wells. Plates were centrifuged
and after 45 min of incubation at 25 °C, fluorescence polariza-
tion was read on a Viewlux microplate reader (PerkinElmer)
using a BODIPY TMR FP filter set and a BODIPY dichroic
mirror (excitation ¼ 525 nm, emission ¼ 598 nm). Fluorescence
polarization was read for 15 seconds for each polarization
plane (parallel and perpendicular). The well fluorescence polar-
ization value (mP) was obtained via the PerkinElmer Viewlux
software. The percent inhibition for each compound was
calculated as follows: Percent inhibition ¼ ðTestCompoundmP-
medianNegativeControlmPÞ∕ðmedianPositive ControlmP-median
NegativeControlmPÞ  100. The test compound was as defined
as wells containing PME-1 in the presence of test compound, ne-
gative controls were defined as wells containing PME-1 and
DMSO, and positive controls were defined as wells containing
no PME-1 protein. A mathematical algorithm was used to deter-
mine nominally inhibiting compounds in the primary screen. Two
values were calculated: (i) the average percent inhibition of
all compounds tested, and (ii) three times their standard devia-
tion. The sum of these two values was used as a cutoff parameter;
i.e.. any compound that exhibited greater inhibition than the
cutoff parameter (26.13%) was declared active. The reported
PubChem Activity Score (http://pubchem.ncbi.nlm.nih.gov/) has
been normalized to 100% observed primary inhibition. Negative
% inhibition values are reported as activity score zero. The activ-
ity score range for active compounds is 100-7, for inactive 7-0.
Cell Culture and Preparation of Human Cell Line Proteomes. MDA-
MB-231 cells were grown in L15 media supplemented with
10% fetal bovine serum at 37 °C in a CO2 free incubator. HEK
293Tcells were grown in DMEM with 10% fetal bovine serum at
37 °C with 5% CO2. For in vitro experiments, cells were grown to
100% confluency, washed two times with PBS, and scraped. Cell
pellets were isolated by centrifugation at 1;400 × g for 3 min. The
pellets were resuspended in 500 μL PBS (pH 7.5), sonicated, and
centrifuged (64;000 × g, 45 min) to provide the soluble fraction
as the supernatant and the membrane fraction as the pellet. For
in situ experiments, compounds were directly added to the cell
culture media for the indicated time before the cells were washed
and scraped. The cell pellets were isolated by centrifugation at
1;400 × g for 3 min, resuspended in 500 μL PBS (pH 7.5),
and sonicated. 250 μL of this total cell extract was saved for
PP2A methylation analysis by Western blotting (described
below), and the remainder was separated into membrane and
soluble fractions as described above. To overexpress PME-1 or
GFP in HEK 293T cells, the genes encoding PME-1 and GFP
were cloned into a modified version of pCLNCX vector (Imge-
nex) and stable cell lines were generated as described previously
(4). Total protein concentration of each fraction was determined
using a protein assay kit (BioRad). Samples were stored at −80 °C
until use.
Competitive ABPP Assays in Proteomes. For in vitro experiments,
proteomes were diluted to 1 mg∕mL in PBS (pH 7.5) and incu-
bated with DMSO or compound for 30 min at 25 °C (25 μL total
reaction volume). FP-rhodamine was then added at a final con-
centration of 2 μM. After 45 min, the reactions were quenched
with 2× SDS/PAGE loading buffer (reducing), separated by SDS/
PAGE (10% acrylamide), and visualized in-gel with a Hitachi
FMBio IIe flatbed fluorescence scanner (MiraiBio). For in situ
experiments, proteomes were diluted to 1 mg∕mL in PBS and
directly labeled with FP-rhodamine (2 μM) for 45 min and
analyzed as described above.
Determination of IC50 Values. For determination of in vitro IC50
values, compounds were incubated in MDA-MB-231 soluble
proteomes (1 mg∕mL, 25 μL total volume) at the indicated
concentrations (performed in triplicate) for 45 min at 37 °C.
The samples were then labeled with FP-rhodamine (2 μM) for
45 min, quenched, separated by SDS/PAGE, and visualized by
in-gel fluorescence scanning. For determination of in situ IC50
values, the soluble fractions from cells treated with compound
(1 h, performed in triplicate) were diluted to 1 mg∕mL in PBS
(25 μL total volume), then labeled with FP-rhodamine (2 μM)
for 45 min, and analyzed as described above. The percentage
activity remaining was determined by measuring the integrated
optical intensity of the bands using ImageJ software. IC50 values
were determined from a dose-response curve generated using
Prism software (GraphPad).
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Assessing the Reversibility of ABL127 Inhibition. Purified wild-type
PME-1 (500 nM, 2.6 mL total volume in PBS) was incubated with
DMSO or ABL127 (5 μM) at 25 °C. After 30 min, 100 μL was
removed from each reaction (Fraction A). The remaining
2.5 mL of each reaction was passaged over a Sephadex G-25M
column (GE Healthcare) and eluted in a volume of 3.5 mL
PBS (Fraction B). 100 μL of both fractions A and B were labeled
with FP-rhodamine (2 μM). After 30 min, the reactions were
quenched with 2× SDS/PAGE loading buffer, separated
by SDS/PAGE, and analyzed by in-gel fluorescence scanning.
Gels were then subjected to Coomassie staining with Instantblue
(Expedeon) to verify equivalent protein loading.
Detection of Modified and Unmodified Tryptic Peptides from ABL127-
Treated Preparations of PME-1. Purified, recombinant PME-1
(10 μM, 25 μl total volume) was incubated with DMSO or
ABL127 (50 μM) for 30 min at 25 °C. Urea (50 mg) was added
to each reaction and the reactions were diluted with PBS (75 μL).
Each sample was then subsequently incubated with tris-(2-car-
boxyethyl)phosphine (TCEP, 5 μL of 100 mM stock) and iodoa-
cetamide (10 μL of 100 mM stock) for 30 min each at 25 °C.
The samples were diluted with ammonium bicarbonate (25 mM,
375 μL) and subjected to trypsin digestion (Promega; 4 μL of
0.5 μg∕μL) overnight at 37 °C in the presence of 2 mM CaCl2.
The next day, samples were concentrated, resuspended in ammo-
nium bicarbonate (25 mM, 100 μL) with 0.1% formic acid, and a
10 μl aliquot was pressure-loaded onto a 100 μm (inner diameter)
fused silica capillary column with a 5 μm tip that contained 10 cm
C18 resin (aqua 5 μm, Phenomenex). LC-MS/MS analysis was
performed on an LTQ-Orbitrap mass spectrometer (Discovery,
ThermoScientific) coupled to an Agilent 1100 series HPLC.
Peptides were eluted from the column using a 125 min gradient
of 5%–100% Buffer B (Buffer B: 20% water, 80% acetonitrile,
0.1% formic acid). The flow rate through the column was
0.25 μl∕min and the spray voltage was 2.5 kV. The LTQ was
operated in data-dependent scanning mode, with one full MS
scan (400–1;600 m∕z) followed by seven MS∕MS scans of the
nth most abundant ions with dynamic exclusion enabled.
For the results shown in Fig. 3, extracted ion chromatograms
(EIC) of the unmodified (top) and ABL127-modified (bottom)
PME-1 peptide containing the active-site serine 156 (blue) were
generated. The mass window for each EIC, the detected high-
resolution mass for each peak, and the charge state for each
tryptic peptide are indicated in the figure. In the DMSO-treated
sample, we observed a large peak with m∕z ¼ 1382.69, corre-
sponding to the 5+ charge state of the unmodified PME-1 active-
site tryptic peptide (top panel, black). In samples treated with
ABL127, however, this peak was absent. Instead, we identified
a peak withm∕z ¼ 1449.13, corresponding to the 5+ charge state
of the ABL127-acylated form of the peptide (bottom panel, red).
As expected, this peak was not present in the DMSO-treated
sample. We found no evidence of carbamoylation of the active-
site serine that could potentially result from nucleophilic attack
on either one of ABL127’s two carbamate groups and would be
distinguishable from β-lactam acylation due to a loss of methanol.
Isotopic Competitive ABPP-MudPIT in Human Cell Lines. Cell culture
was performed as described above except MDA-MB-231 cells
were grown in RPMI-1640 SILAC media (ThermoScientific)
and HEK 293Tcells were grown in DMEM SILAC media (Ther-
moScientific) supplemented with dialyzed fetal bovine serum
(Gemini) and 12C14N-lysine and -arginine (Sigma) (“light” cells)
or 13C6
15N2-lysine and -arginine (Isotec) (“heavy” cells). Cells
were treated as indicated with DMSO or compound (1 h), and
soluble and membrane proteomes were isolated as described
above. Light and heavy proteome fractions (0.5 mg each) were
combined (1 mL total volume) and were labeled with 5 μM
of FP-biotin for 1 hr at 25 °C. After incubation, the membrane
proteomes were solubilized with 1% Triton-X and rotated at
4 °C for 1 hr. Enrichment of FP-labeled proteins was achieved
as previously described (5, 6). The streptavidin-enriched pro-
teome was washed two times for 3 min with (1) 1% SDS in
PBS, (2) 6 M urea in PBS, (3) PBS (pH 7.5), and finally resus-
pended in 200 μL 8 M urea in 25 mM ammonium bicarbonate.
Samples were then prepared for on-bead digestion by reduction
with 10 mM TCEP (Sigma) for 30 min at 25 °C and alkylation
with 12 mM iodoacetamide (Sigma) for 30 min at 25 °C in the
dark. Samples were diluted to 2 M urea with PBS (pH 7.5)
and digestions were performed for 12 hr at 37 °C with trypsin
(Promega; 4 μL of 0.5 μg∕μL) in the presence of 2 mM CaCl2.
Lastly, peptide samples were acidified to a final concentration
of 5% formic acid.
Digested peptide mixtures were pressure-loaded on a fused
silica loading column (250 micron i.d., 360 micron o.d.) packed
with 4 cm of reversed-phase resin (Aqua C18, 5micron, 125A,
Phenomenex) fitted with the fritted filter (Upchurch). The load-
ing column was attached in-line to a biphasic MudPIT capillary
column [100micron i.d., 360micron o.d., packed with 10 cm
Aqua C18 reversed-phase resin followed by 3 cm strong cation
exchange resin (Partisphere, 5micron, 120A, Whatman) with an
in-house pulled tip]. The sample was analyzed by two-dimen-
sional liquid chromatography (2D-LC) separation in combination
with tandem mass spectrometry as previously described (6, 7)
using an Agilent 1100-series quaternary pump (manual flow-split
system) and LTQ-Orbitrap (Discovery for HEK 293T sample
analysis or Velos for MDA-MB-231 sample analysis) mass spec-
trometer using Xcalibur Software (ThermoScientific) outfitted
with an in-house fabricated nano-spray platform. Peptides were
eluted in a five-step MudPIT experiment (using 0%, 10%, 25%,
80%, and 100% salt bumps of 500 mM aqueous ammonium
acetate, each step followed by an increasing gradient of aqueous
acetonitrile/0.1% formic acid) and data were collected in data-
dependent acquisition mode with dynamic exclusion enabled
(repeat count of 1, exclusion duration of 60 s for Discovery or
20 s for Velos). One full MS1 scan (400–1800 m∕z) was followed
by a series of data-dependent MS2 scans (seven for Discovery,
30 for Velos) of the most abundant ions with monoisotopic
precursor selection enabled. All other parameters were left at
default values. The MS2 spectra data were extracted from the
raw file using RAW Xtractor (version 1.9.7; publicly available
at http://fields.scripps.edu/?q=content/download). MS2 spectra
data were searched using the SEQUESTalgorithm (Version 3.0)
(8) against the latest version of the human IPI database conca-
tenated with the reversed database for assessment of false-discov-
ery rate (9). SEQUEST searches allowed for variable oxidation
of methionine (þ16), static modification of cysteine residues
(þ57 due to alkylation), and no enzyme specificity. Each dataset
was independently searched with light and heavy params files. For
the light search, all other amino acids were left at default masses;
for the heavy search, static modifications on lysine (8.0142) and
arginine (10.0082) were specified. The resulting MS2 spectra
matches were assembled into protein identifications and filtered
using DTASelect (version 2.0.41) (10) with the –trypstat option,
which applies different statistical models for the analysis of tryp-
tic, half-tryptic, nontryptic peptides, and peptides were restricted
to fully tryptic using the -y 2 option. DTASelect 2.0 uses a quad-
ratic discriminant analysis to achieve a user-defined maximum
peptide false positive rate; the default parameters (maximum
false positive rate of 5%) was used for the search; however, the
actual false positive rate was much lower (<1%). SILAC ratios
were quantified using in-house software (11). The total proteomic
data was filtered manually for serine hydrolases containing at
least two quantifiable peptides, and data was globally normalized
to a control sample where both heavy and light cells were treated
with DMSO and mixed in a 1∶1 ratio to adjust heavy to light
peptide abundance to exactly a 1∶1 ratio (correction factor ¼
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1.3light∕heavy). In the HEK 293T cell lines, two serine hydro-
lases, BCHE and CES3, displayed ratios >3light : 1heavy in
the control sample that were maintained in the inhibitor-treated
sample, and, for simplicity, were excluded from analysis.
Chemistry Space Analysis of the MLPCN Library. Chemistry space
coordinates for the chemical structures of and 315,002 MLSMR
substances that were screened against PME1 were generated
using the software package Diverse Solutions 6.3.2. (Tripos Inc.)
following the described methodology (12). 16,000 compounds
from the Maybridge compound collection that were screened as
a preliminary test of the PME-1 fluopol-ABPP assay were also
included in this analysis. Standard hydrogen-suppressed binary
BCUTS descriptors were generated from the 2D structures fol-
lowed by optimization of the chemistry space allowing a maxi-
mum of 16 dimensions as described. A 5D chemistry space
was obtained:
0.280418 0.509676 NLScaling[0.395317,0.117725] of
bcut_gastchrg_burden_000.100_R_H.bdf:BCUT, diag =
Gast.-Huckel charges, off-diag = 10 * Burden’s nums *
0.100, remove Hs, high eig
-0.547135 -0.366027 NLScaling[-0.456299,0.0908346] of
bcut_gastchrg_burden_000.100_R_L.bdf:BCUT, diag =
Gast.-Huckel charges, off-diag = 10 * Burden’s nums *
0.100, remove Hs, low eig
7.64428 10.0443 NLScaling[8.94606,1.30650] of
bcut_haccept_burden_002.500_R_H.bdf:BCUT, diag = h-bond
acceptor, off-diag = 10 * Burden’s nums * 2.500, remove
Hs, high eig
1.72605 2.56110 NLScaling[2.14481,0.423132] of
bcut_hdon or_burden_000.600_R_H.bdf:BCUT, diag = h-bond
donor, off-diag = 10 * Burden’s nums * 0.600, remove Hs,
high eig
2.73170 3.58307 NLScaling[3.16957,0.442155] of
bcut_tabpolar_burden_000.500_R_H.bdf:BCUT, diag = tab
polar (A3), off-diag = 10 * Burden’s nums * 0.500, remove
Hs, high eig
Chemistry space coordinates and cell indices using 10 bins per
coordinate were then generated (105 cells). 12 Maybridge and
746 MLSMR compounds fall outside the space. 12,660 cells
are occupied ranging between 1 and 3335 compounds. Figure 2B
shows all compounds in the first two chemistry space coordinates
(the remaining three dimensions are projected into the area
shown). The 26 ABLS are shown as (enlarged) squares, other
compounds are shown as small circles (dots). Cell occupancy is
mapped onto the space and shown by the color of the compounds
with red indicating high occupancy and blue the lowest occu-
pancy, illustrating the relatively lower density of the space occu-
pied by the ABLs. The zoomed subspace occupied by the ABLs is
shown separately. As expected the most active compounds
ABL127 and ABL103 are very close neighbors in this space.
Evaluation of Serine Hydrolases Targeted by ABL127 in Vivo.C57BL/6
mice were treated intraperitoneally with vehicle (18∶1∶1 Saline:
Emulphor:DMSO) or ABL127 (50 mgkg−1). After 2 hours, the
animals were sacrificed and the soluble and membrane fractions
of brains were isolated following previously described methods
(5). Briefly, mouse brains were Dounce-homogenized in PBS
(pH 7.5) followed by a low-speed spin (1;400 × g, 5 min) to
remove debris. The supernatant was then subjected to centrifu-
gation (64;000 × g, 45 min) to provide the soluble fraction as the
supernatant and the membrane fraction as the pellet. The soluble
proteomes (1 mg∕mL) were treated with DMSO or ABL127
(2 μM) for 30 min before incubation with FP-rhodamine
(2 μM) for 45 min at 25 °C (25 μL total reaction volume). Reac-
tions were quenched with one volume of standard 2x SDS/PAGE
loading buffer (reducing), separated by SDS/PAGE (10% acryla-
mide), and visualized by in-gel fluorescence scanning.
In addition, both the membrane and soluble proteomes of
these brains (1 mg∕mL in PBS; 1 mL total volume) were pre-
pared for analysis by ABPP-MudPIT using the FP-Biotin probe
as described above. Peptides were eluted in a 5-step MudPIT
experiment (using 0%, 10%, 25%, 80%, and 100% salt bumps
of 500 mM aqueous ammonium acetate) and data were collected
in data-dependent acquisition mode with dynamic exclusion
turned on (60 s, repeat of 1) on a Thermo Scientific LTQ ion trap
mass spectrometer. Specifically, one full MS (MS1) scan (400–
1800 m∕z) was followed by 7 MS2 scans of the most abundant
ions. The MS2 spectra data were extracted from the raw file using
RAW Xtractor (version 1.9.7; publicly available at http://fields.
scripps.edu/?q=content/download). MS2 spectra data were
searched using the SEQUESTalgorithm (Version 3.0) (8) against
the latest version of the mouse IPI database concatenated with
the reversed database for assessment of false-discovery rates
(9). SEQUESTsearches allowed for variable oxidation of methio-
nine (þ16), static modification of cysteine residues (þ57 due to
alkylation), and no enzyme specificity. The resulting MS2 spectra
matches were assembled into protein identifications and filtered
using DTASelect (version 2.0.41) (10) using the –trypstat option.
The total proteomic data was filtered for serine hydrolases manu-
ally. Serine hydrolases that displayed an average of ≥10 spectral
counts from three independent runs are shown.
Immunoblot Analysis. The whole proteomes of cell lines or mouse
brains (treated as indicated) were diluted to 2 mg∕ml in PBS,
denatured with standard 2x SDS/PAGE loading buffer (redu-
cing), separated by SDS/PAGE (10% acrylamide), and analyzed
by western blotting using standard methods. Blots were probed
using indicated antibodies following manufacturers’ instructions,
and were visualized and quantified using the Odyssey Imaging
System (Li-Cor).
Cycloaddition Reactionswith the Clickable Probe ABL112.Click chem-
istry was performed following previously described protocols
(13). For in vitro experiments, soluble proteomes (0.5 mg∕mL
in PBS) were incubated with DMSO, ABL127, or ent-ABL127 at
25 °C for 30 minutes prior to incubation with ABL112 for 30 min.
For in situ experiments, MDA-MB-231 cells were incubated with
DMSO or ABL127 for 30 min prior to addition of ABL112 for
2 h. The soluble proteomes from these cells were isolated as de-
scribed above and diluted to 0.5 mg∕mL in PBS. Alkyne-labeled
proteomes were then incubated rhodamine-azide (50 μM), fol-
lowed by TCEP (1 mM), ligand (100 μM), and CuSO4 (1 mM).
After 1 h at 25 °C, reactions were analyzed by SDS-PAGE and
in-gel fluorescence scanning.
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ABL Synthetic Methods
General Information.Analytical data and procedures for the ABLs
in the initial screening are reported in our previous work (14).
Nucleophilic catalyst PPY* was prepared by literature methods
(15). Hydrazine hydrate (Aldrich), propargyl chloroformate
(Aldrich), pyridine (Alfa Aesar), K2CO3 (Alfa Aesar), absolute
ethanol (Pharmco-Aaper), and anhydrous CH2Cl2(Aldrich) were
purchased and used as received. N-Bromosuccinimide was pur-
chased from Alfa Aesar and recrystallized from H2O prior to use.
Cyclopentyl phenyl ketene was prepared according to our pre-
viously reported ketene synthesis method (16) from commercially
available α-cyclopentylphenylacetic acid (MP Biomedicals) and
spectral data matched those previously reported (17). Dimethy-
lazodicarboxylate was purchased from Wako or prepared by
literature methods (18).
.
Dimethyl 3-cyclopentyl-4-oxo-3-phenyl-1,2-diazetidine-1,2-dicarboxy-
late (ABL127). (14): In a nitrogen-atmosphere glovebox, a solution
of cyclopentyl phenyl ketene (921.4 mg, 4.95 mmol, 1.0 equiv) in
CH2Cl2 (350 mL) was prepared in a 500 mL round bottom flask.
A solution of dimethylazodicarboxylate (722.8 mg, 4.95 mmol, 1.0
equiv) in CH2Cl2 (8 mL) was added and the flask was sealed with
a rubber septum. In a separate vial, a solution of (−)-PPY*
(93.1 mg, 0.25 mmol, 0.05 equiv) in CH2Cl2 (4 mL) was prepared
and the vial was closed with a septum cap. The flask and vial were
removed from the glovebox and the flask containing the golden
yellow ketene/azodicarboxylate solution was cooled to −20 °C in
an immersion bath. The dark purple catalyst solution was added
via syringe leading to an immediate color change to deep blue.
The mixture was stirred at −20 °C overnight, and then warmed
to ambient temperature and concentrated under vaccum. Flash
column chromatography on SiO2 using 20% EtOAc in hexanes as
eluent (Rf ∼ 0.2) provided ABL127 as a colorless oil (1.3325 g,
84% yield). Spectral data matched those previously reported
(14). HPLC analysis found 86% ee (4.6 × 250 mm Chiralpak
AD-H column, 10% i-PrOH in hexanes eluent, isocratic 1.0 mL∕
min flow rate, retention times: 18.4 min (minor), 26.6 min
(major)).
Separation of enantiomers was achieved by semipreparative
HPLC (10 × 250 mmChiracel OD-H column, 1% i-PrOH in hex-
anes eluent, isocratic 2.75 mL∕min flow rate) provided samples
of both ABL127 (major component, retention time: 29.5 min)
and ent-ABL127 (minor component, retention time: 27.2 min)
with >99% ee
.
Propargyl Hydrazidodicarboxylate (19). To a stirred 0 °C solution of
hydrazine hydrate (250.3 mg, 5.0 mmol, 1.0 equiv) in absolute
ethanol (3 mL) was added neat propargyl chloroformate
(975.5 μL, 10.0 mmol, 2.0 equiv) dropwise. White precipitate
formed immediately. When one quarter of the chloroformate
had been added, addition of a solution of K2CO3 (1.38 g,
10.0 mmol, 2.0 equiv) in deionized water (3 mL) was commenced.
The two liquids were added dropwise simultaneously at such a
rate that the chloroformate addition was complete just before
the addition of the base solution was completed. The resulting
heterogeneous mixture was stirred for 1.5 h, during which time
it warmed to ambient temperature. The white solid was separated
by vacuum filtration through a sintered glass frit and dried on the
frit for 45 min. The solid was collected in a vial and further dried
under vacuum overnight to provide the hydrazide as a free-flow-
ing white powder (727.9 mg, 74% yield).
1H NMR (500 MHz, CD3OD) δ 4.72 (d, J ¼ 2.3 Hz, 4H), 2.92
(t, J ¼ 2.3 Hz, 2H);
13C NMR (125 MHz, CD3OD) δ 158.1, 78.8, 76.4, 53.9;
IR (neat film, NaCl) 3284, 2409, 1704, 1692, 1415, 1341, 1271,
1117, 775, 694, 658 cm−1
LRMS (ES+) m∕z: cacld for C8H9N2O4½MþHþ: 197.1,
found 197.0
.
Dipropargyl Azodicarboxylate (18). Propargyl hydrazidodicarboxy-
late (150.0 mg, 0.76 mmol, 1.0 equiv) was suspended in a mixture
of CH2Cl2 (4 mL) and deionized water (3 mL). Pyridine (56.9 μL,
0.70 mmol, 0.92 equiv) was added to the suspension in one por-
tion and then the mixture was cooled to 0 °C. Solid N-bromosuc-
cinimide (136.1 mg, 0.76 mmol, 1.0 equiv) was added in one
portion leading to an immediate color change of the organic
phase to yellow-orange. The mixture was stirred for 30 min at
0 °C during which time all the solid materials dissolved. The clear
colorless aqueous phase was removed and the remaining yellow-
orange colored organic phase was washed with water (4 × 2 mL).
The organics were dried over MgSO4, filterered, and concen-
trated under vacuum. The residue was dissolved in toluene
(3 mL) and then concentrated again under vacuum to afford an
orange oil (136.5 mg, 92% yield) that was used without further
purification.
1H NMR (500 MHz, CDCl3) δ 5.02 (app dd, J ¼ 2.4, 1.3 Hz,
4H), 2.65 (app dt, J ¼ 2.4, 1.3 Hz, 2H);
13C NMR (125 MHz, CDCl3) δ 159.4, 77.6, 75.3, 56.5;
IR (neat film, NaCl) 2134, 1788, 1441, 1371, 1267, 1214, 1027,
990, 944, 879, 859, 805, 694, 646, 539 cm−1;
LRMS (ES+) m∕z: cacld for C8H6N2O4Na½MþNaþ: 217.0,
found 217.0
.
Dipropargyl 3-cyclopentyl-4-oxo-3-phenyl-1,2-diazetidine-1,2-dicar-
boxylate (ABL112) (14). In a nitrogen-atmosphere glovebox, a solu-
tion of cyclopentyl phenyl ketene (88.9 mg, 0.48 mmol, 1.0 equiv)
in CH2Cl2 (30 mL) was prepared in a 100 mL round bottom flask.
A solution of freshly prepared dipropargyl azodicarboxylate
(92.7 mg, 0.48 mmol, 1.0 equiv) in CH2Cl2 (4 mL) was added
and the flask was sealed with a rubber septum. In a glass vial,
a solution of (±)-PPY* (9.0 mg, 0.024 mmol, 0.05 equiv) in
CH2Cl2 (1 mL) was prepared and the vial was sealed with a
septum cap. Both the flask and the vial were removed from
the glovebox. The flask containing the golden yellow ketene/
azodicarboxylate solution was cooled to −20 °C in an immersion
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bath. After 20 min, the dark purple catalyst solution was added
to the flask via syringe in one portion. The reaction mixture
immediately darkened to a deep blue color. The mixture was
stirred at −20 °C for 15 h, and then warmed to ambient tempera-
ture and concentrated under vacuum. The residue was purified
by gradient flash chromatography on SiO2 using 5–10% EtOAc
in hexanes as eluent. The product was isolated as a viscous color-
less oil (142.0 mg, 78% yield).
1H NMR (500 MHz, CDCl3) δ 7.59 (dd, J ¼ 7.8, 1.4 Hz, 2H),
7.43–7.35 (m, 3H), 4.88 (app d, J ¼ 2.5 Hz, 2H), 4.87–4.66 (br m,
2H), 3.02–2.93 (m, 1H), (dd, J ¼ 2.5, 0.7 Hz, 1H), 2.53 (app t,
J ¼ 2.4 Hz, 1H), 1.90 (br s, 1H), 1.77–1.63 (m, 4H), 1.62–1.52
(m, 1H), 1.53–1.40 (m, 2H);
13C NMR (125 MHz, CDCl3) δ 163.9, 156.7, 147.2, 129.1,
128.7, 126.5, 76.7 (2C), 76.2, 76.1, 55.2, 54.6, 44.8, 29.0, 27.7,
25.8, 25.5;
IR (neat film, NaCl) 2950, 2871, 2361, 2330, 1836, 1773, 1741,
1449, 1436, 1377, 1307, 1267, 1224, 1187, 1128, 1062, 997 cm−1;
LRMS (ES+) m∕z: cacld for C21H21N2O5½MþHþ: 381.1,
found: 381.1
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Fig. S1. Competitive ABPP in soluble lysates of PME-1-transfected HEK 293T cells (1 mg∕mL protein) identifies ABLs (1 μM) as selective inhibitors of PME-1.
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Fig. S2. Concentration-dependent PME-1 inhibition profiles in the soluble proteome of MDA-MB-231 cells (1 mg∕mL protein) determined by competitive
ABPP for (A) ABL127 (IC50 ¼ 4.2 nM; 95% confidence limits 2.3–7.5 nM), (B) ent-ABL127 (IC50 ¼ 450 nM; 95% confidence limits 240–850 nM), (C) ABL103
(IC50 ¼ 2.1 nM; 95% confidence limits 0.6–7 nM), (D) ABL105 (IC50 ¼ 92 nM; 95% confidence limits 50–170 nM), and (E) ABL107 (IC50 ¼ 24 nM, 95% confidence
limits 11–53 nM). For each profile, the region containing PME-1 of a representative competitive ABPP gel is shown above the IC50 curve. Data are presented as
mean values SEM; n ¼ 3∕group.
Fig. S3. ABL127 selectively inactivates PME-1 in HEK 293T cells. (A) Gel-based competitive ABPP profiles of the soluble proteomes from HEK 293T cells
(1 mg∕mL total protein) treated with a concentration range of ABL127 (0.61–10,000 nM; 1 h) reveals selective blockade of PME-1 with (B) an IC50 value
of 6.4 nM (95% confidence limits 2.2–19 nM). Data are presented as mean values SEM; n ¼ 3∕group.
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Fig. S4. SILAC-ABPP experiments reveal selective PME-1 inhibition by ABL127 in situ. (A) Isotopically “light” and “heavy”MDA-MB-231 cells were treated with
DMSO or ABL127 (500 nM), respectively, for 1 h. Proteomes were combined in a 1∶1 total protein ratio (0.5 mg each) and analyzed by ABPP-MudPIT. Serine
hydrolase activities were quantified by comparing intensities of light and heavy peptide peaks. (B) Isotopically “light” and “heavy”HEK 293Tcells were treated
with DMSO and ABL127 (100 nM), respectively, for 1 h, and analyzed as described above. Data are presented as mean values SEM for all quantifiable peptides
from each serine hydrolase.
Fig. S5. Evaluation of ABL112 by competitive ABPP. (A) ABL112 inactivates PME-1 in the MDA-MB-231 soluble proteome (1 mg∕mL protein, 1 h) with an IC50
value of 13.8 nM (95% confidence limits 6.5–29 nM). Data are presented as mean values SEM; on ¼ 3∕group. (B) MDA-MB-231 soluble lysates (0.5 mg∕mL)
were incubated (30 min) with DMSO, ABL127 (100 nM), or ent-ABL127 (100 nM). ABL112 (50 nM) was then added for an additional 30 minutes before per-
forming a “click” reaction with RhN3, followed by separation by SDS/PAGE, and visualization by in-gel fluorescence scanning. (C) ABL112 (2.5 μM), but not
ABL127 (2.5 μM), blocks FP-Rh labeling of an approximately 80 kDa serine hydrolase in the MDA-MB-231 soluble proteome.
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Table S1. Structures of all 26 ABLs in the MLPCN library
Inactive enantiomers (of active ABLs)
# Structure CID Primary (%)Conf (%) # Structure CID Primary (%)
1 (ABL103) 24856231 70.99 76.56q 5 (ent-ABL103) 24856324 9.16
2 (ABL127) 24856225 69.6 86.91 6 (ent-ABL127) 24856313 22.86
3 (ABL105) 24856234 49.08 48.17 7 (ent-ABL105) 24856237 5.32
4 (ABL107) 24856222 33.67 40.82
Inactive ABLs Inactive enantiomers (of inactive ABLs)
8 24856236 34.64 23.33 19 24856238 11
9 24856321 25.21 -
10 24856323 15.01 - 20 24856233 2.35
11 24856226 1.48 - 21 24856224 27.61
12 24856228 −3.25 - 22 24856230 7.87
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Inactive enantiomers (of active ABLs)
# Structure CID Primary (%)Conf (%) # Structure CID Primary (%)
13 24856322 0.36 - 23 24856223 −1.97
14 24856235 4.09 -
15 24856227 −5.78 - 24 24856229 3.22
16 24856232 −3.06 - 25 24856326 −2.44
17 24856314 4.87 - 26 24856325 −1.35
18 24892492 −0.67 -
Percent PME-1 inhibition values in the primary and, if applicable, confirmation (conf) screens are shown. Complete PME-1 screening data is publicly
available in the PubChem online database (http://pubchem.ncbi.nlm.nih.gov/). CID, compound identification number in the MLPCN library.
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